ストックスクリーナーアプリを入手
38.38
0.53%
-0.13
前日終値:
$38.51
開ける：
$38.01
24時間の取引高:
19,057
Relative Volume:
0.05
時価総額：
$2.43B
収益：
-
当期純損益:
$-80.77M
株価収益率:
-30.22
EPS:
-1.27
ネットキャッシュフロー:
$-80.80M
1週間 パフォーマンス:
+1.82%
1か月 パフォーマンス:
-3.05%
6か月 パフォーマンス:
-29.48%
1年 パフォーマンス:
-4.14%
1日の値動き範囲:
$37.92
$38.54
1週間の範囲:
$37.76
$40.49
52週間の値動き範囲:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
38.30 | 2.39B | 0 | -80.77M | -80.80M | -1.27 |
|
ONC
Beigene Ltd Adr
|
241.26 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.26 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.48 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.11 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Wolfe Research lifts Moonlake stock to Outperform By Investing.com - Investing.com Canada
Wolfe Research lifts Moonlake stock to Outperform - Investing.com Australia
Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock News - GuruFocus
Wolfe upgrades MoonLake Immunotherapeutics ahead of sonelokimab data - TipRanks
Wolfe Research Upgrades MoonLake (MLTX) to Outperform with New P - GuruFocus
MoonLake Immunotherapeutics Stock Gains Momentum - TipRanks
Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform - marketscreener.com
Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX), Sets $61 Target | MLTX Stock News - GuruFocus
Ameriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Wedbush Issues Positive Forecast for MLTX Earnings - Defense World
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet - MSN
RBC Capital Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake Immunotherapeutics: Buy Rating Driven by Strategic Developments and Promising Clinical Programs - TipRanks
Dimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Needham Reiterates Buy Rating for MoonLake (MLTX) with Price Tar - GuruFocus
MoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy Rating - TipRanks
Decoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT In - GuruFocus
Promising Growth Potential and Financial Strength Drive Buy Rating for MoonLake Immunotherapeutics - TipRanks
MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating - TipRanks
MoonLake Immunotherapeutics Q1 Loss Widens - marketscreener.com
MoonLake Immunotherapeutics (MLTX) Strengthens Financial Positio - GuruFocus
MoonLake Immunotherapeutics reports results for the quarter ended March 31Earnings Summary - TradingView
MoonLake Immunotherapeutics reports Q1 EPS (63c), consensus (74c) - TipRanks
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
Hot Picks in biotechnology - BNN Bloomberg
In the Green: MoonLake Immunotherapeutics (MLTX) Closes at 37.60, Up/Down -4.24 from Previous Day - DWinneX
MoonLake Immunotherapeutics’ SWOT analysis: biopharma stock faces challenges and opportunities - Investing.com Canada
Mariner LLC Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
The biggest biotech funding rounds in April 2025 - Labiotech.eu
MoonLake Immunotherapeutics’ (MLTX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
(MLTX) Investment Analysis - news.stocktradersdaily.com
MoonLake Immunotherapeutics: Promising Clinical Updates and Market Potential Support Buy Rating - TipRanks
RBC Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake Immunotherapeutics (MLTX) receives an Outperform rating from RBC Capital Mkts - knoxdaily.com
MoonLake Immunotherapeutics Shares Surge Ahead of Key Event - TipRanks
MoonLake Immunotherapeutics price target raised to $85 from $81 at BTIG - TipRanks
MoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy Rating - TipRanks
BTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock News - GuruFocus
MoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy Rating - TipRanks
MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating - TipRanks
Ratio Analysis: Unpacking MoonLake Immunotherapeutics (MLTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
MoonLake Immunotherapeutics Hosts Capital Markets Day - TipRanks
Geode Capital Management LLC Purchases 540 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
LPL Financial LLC Buys 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - American Banking and Market News
LPL Financial LLC Purchases 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - GlobeNewswire
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
13.67%
大文字化:
|
ボリューム (24 時間):